MedDataX Logo

Pregabalin In Partial Seizures Extension Study

NCT ID: NCT00143130

Last Updated: 2021-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

227 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

NCT00141427

Seizures
COMPLETED PHASE4

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NCT00143143

Epilepsies, Partial Epilepsy, Complex Partial
COMPLETED PHASE3

Pregabalin Epilepsy Add-On Trial

NCT00141258

Partial Seizures
COMPLETED PHASE3

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

NCT00407797

Partial Seizures
TERMINATED PHASE4

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336

Seizure Disorder, Partial
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seizures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Group Type EXPERIMENTAL

Pregabalin

Intervention Type DRUG

Pregabalin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

Pregabalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* have completed the 21-week study and have shown a significant clinical response and wish to continue treatment


* Having a treatable cause of seizure.
* Having a progressive neurological or systemic disorder
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Bruges, , Belgium

Site Status

Pfizer Investigational Site

Brussels, , Belgium

Site Status

Pfizer Investigational Site

Duffel, , Belgium

Site Status

Pfizer Investigational Site

Ghent, , Belgium

Site Status

Pfizer Investigational Site

Leuven, , Belgium

Site Status

Pfizer Investigational Site

Liège, , Belgium

Site Status

Pfizer Investigational Site

Tielt, , Belgium

Site Status

Pfizer Investigational Site

Yvoir, , Belgium

Site Status

Pfizer Investigational Site

Helsinki, , Finland

Site Status

Pfizer Investigational Site

Kuopio, , Finland

Site Status

Pfizer Investigational Site

Tampere, , Finland

Site Status

Pfizer Investigational Site

Paris, Cedex 14, France

Site Status

Pfizer Investigational Site

Lille, Cedex, France

Site Status

Pfizer Investigational Site

Lyon, Cedex, France

Site Status

Pfizer Investigational Site

Marsille, Cedex, France

Site Status

Pfizer Investigational Site

Rennes, Cedex, France

Site Status

Pfizer Investigational Site

Bayonne, , France

Site Status

Pfizer Investigational Site

Bordeaux, , France

Site Status

Pfizer Investigational Site

Grenoble, , France

Site Status

Pfizer Investigational Site

Marseille 13, , France

Site Status

Pfizer Investigational Site

Montpellier, , France

Site Status

Pfizer Investigational Site

Nancy, , France

Site Status

Pfizer Investigational Site

Nice, , France

Site Status

Pfizer Investigational Site

Paris, , France

Site Status

Pfizer Investigational Site

Paris, , France

Site Status

Pfizer Investigational Site

Paris, , France

Site Status

Pfizer Investigational Site

Strasbourg, , France

Site Status

Pfizer Investigational Site

Toulouse, , France

Site Status

Pfizer Investigational Site

Tours, , France

Site Status

Pfizer Investigational Site

Katowice, , Poland

Site Status

Pfizer Investigational Site

Krakow, , Poland

Site Status

Pfizer Investigational Site

Lublin, , Poland

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Warsaw, , Poland

Site Status

Pfizer Investigational Site

Wroclaw, , Poland

Site Status

Pfizer Investigational Site

Braga, , Portugal

Site Status

Pfizer Investigational Site

Coimbra, , Portugal

Site Status

Pfizer Investigational Site

Funchal, , Portugal

Site Status

Pfizer Investigational Site

Lisbon, , Portugal

Site Status

Pfizer Investigational Site

Matosinhos Municipality, , Portugal

Site Status

Pfizer Investigational Site

Ponta Delgada, , Portugal

Site Status

Pfizer Investigational Site

Ponta Delgada, , Portugal

Site Status

Pfizer Investigational Site

Porto, , Portugal

Site Status

Pfizer Investigational Site

Lausanne, , Switzerland

Site Status

Pfizer Investigational Site

Zurich, , Switzerland

Site Status

Pfizer Investigational Site

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Finland France Poland Portugal Switzerland

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081015&StudyName=Pregabalin%20In%20Partial%20Seizures%20Extension%20Study

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0081015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
NCT00141388 COMPLETED PHASE3
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00150293 COMPLETED PHASE3
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
NCT00596466 COMPLETED PHASE3
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
NCT00524030 TERMINATED PHASE3
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00141245 COMPLETED PHASE3
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
NCT00141414 COMPLETED PHASE2
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
NCT00448916 COMPLETED PHASE3
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306 COMPLETED PHASE3
Once-A-Day Pregabalin For Partial Seizures
NCT01262677 COMPLETED PHASE3
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281 COMPLETED PHASE1/PHASE2
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
NCT01389596 COMPLETED PHASE3
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824 COMPLETED PHASE3
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
NCT01747915 COMPLETED PHASE3
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
NCT00372528 TERMINATED PHASE3
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059 COMPLETED PHASE3
Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
NCT01309074 WITHDRAWN PHASE4
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
NCT00684424 COMPLETED
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
NCT01147003 COMPLETED PHASE2
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00288639 COMPLETED PHASE4
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 COMPLETED PHASE4
Phase II BGG492 Capsule Extension for Partial Epilepsy
NCT01338805 COMPLETED PHASE2
Clinical Study With Lyrica In Patients Suffering From Epilepsy
NCT00922987 COMPLETED
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
NCT01002820 COMPLETED PHASE2
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
NCT00175864 WITHDRAWN PHASE3
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 WITHDRAWN PHASE2